Otros idiomas MoonLake Immunotherapeutics

Acciones

MLTX

KY61559X1045

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 14/07/2026			Variación 5 días	Varia. 1 de enero.
19,52 ^USD	-4,36 %		+1,93 %	+48,10 %

24/06	Fondos cotizados y futuros sobre acciones, al alza antes de la apertura del miércoles tras relajarse las tensiones entre Estados Unidos e Irán	MT
24/06	MoonLake Immunotherapeutics fija en 200.000 millones USD una oferta pública	MT

Otros idiomas

24/06	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensions
24/06	MoonLake Immunotherapeutics Prices $200 Million Public Offering
24/06	MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
23/06	Moonlake Immunotherapeutics Insider Sold Shares Worth $862,205, According to a Recent SEC Filing
23/06	USA-Les valeurs à suivre à Wall Street (actualisé)
22/06	MoonLake Immunotherapeutics Plans $150 Million Public Offering
22/06	MoonLake Immunotherapeutics Announces Proposed Public Offering
21/06	MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
21/06	Moonlake Immunotherapeutics Announces Week 52 Results of Sonelokimab from Its Phase 3 Vela Program in Hidradenitis Suppurativa
11/05	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2026
11/05	MoonLake Immunotherapeutics Q1 Net Loss Widens
11/05	MoonLake Immunotherapeutics Q1 Net Loss Widens
10/05	MoonLake Immunotherapeutics says U.S. FDA accepts MIRA and VELA-TEEN trial data for sonelkimab BLA submission
10/05	MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
10/05	MoonLake Immunotherapeutics Announces Positive Outcome from Its Final Pre-BLA Meeting with the U.S. FDA
15/04	Moonlake Immunotherapeutics Insider Sold Shares Worth $2,752,163, According to a Recent SEC Filing
13/04	Moonlake Immunotherapeutics Insider Sold Shares Worth $1,663,935, According to a Recent SEC Filing
30/03	MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says
30/03	MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
28/03	Moonlake Immunotherapeutics Announces Week 40 Results from Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa
28/03	MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
23/03	MoonLake Immunotherapeutics Shares Rise After Wolfe Research Upgrade
19/03	MoonLake Immunotherapeutics Shares Rise After Rothschild & Co Redburn Upgrade
25/02	MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2025
23/02	MoonLake Immunotherapeutics : Investor Day (Feb 2026)